Spanish plasma-derived biopharmaceutical company making treatments from blood plasma for immune and rare disorders.
Spanish plasma-derived biopharmaceutical company making treatments from blood plasma for immune and rare disorders.
Collects plasma, the liquid part of blood, from paid donors at its own donation centres, mostly in the US, then processes it into medicines sold to hospitals and through distributors. Plasma supply rather than demand is the limit, so donor volumes shape cost. The founding Grifols family remains an important shareholder.
In one line: A Spanish peer to CSL Limited/CSL Behring.
Moat: narrow (scale, regulatory licence, installed base). Owns one of the world's largest plasma-collection networks, a capital- and regulation-intensive barrier to entry.
Headquarters: Barcelona, Spain · Founded: 1940 · Employees: 25,258
Size Grifols (GRF.MC) is a Spain Health Care company (Pharmaceuticals: Major) with a market value of $7.48B, the 24th largest of 93 Spain companies the cockpit tracks. Shares closed at €11.41 on 18 Nov 2026.
Performance Over six months the shares gained 18.7%, against +2.7% for the median peer and +5.3% for the Spain market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 1.0% over the last twelve months (peer median +13.9%); the operating margin is 16.4% (peer median 13.8%).
Valuation It trades at 13.1× forward earnings against a peer median of 19.2× (3rd cheapest of 16).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -0 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.8 points below its cost of capital (8.2% WACC).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €7.60B | €7.52B | €7.21B | €6.59B | €6.06B |
| Revenue growth | — | +4% | +9% | +9% | — |
| Gross profit | €2.82B | €2.69B | €2.63B | €2.31B | €2.10B |
| EBITDA | €1.70B | €1.69B | €1.56B | €1.14B | €1.09B |
| Net income | €487M | €402M | €157M | €42.3M | €208M |
| Free cash flow | €847M | €782M | €670M | -€5.75M | -€267M |
| Capital expenditure | €453M | €423M | €371M | €310M | €376M |
| Total debt | €9.24B | €8.74B | €9.20B | €10.1B | €9.75B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Grifols GRF.MC | $7.48B | +19% | +1% | 16% | 13.1× | 7.1% |
| CSL CSL.AX | $63.7B | +102% | -2% | 26% | 21.5× | 6.8% |
| Takeda Pharmaceutical 4502.T | $69.8B | +30% | +6% | 18% | 51.0× | 3.7% |
| ADMA Biologics ADMA | $3.01B | +58% | +6% | 45% | 16.7× | -0.8% |
| Kamada KMDA | $465M | +3% | +5% | 15% | 17.9× | 5.0% |
| GC Biopharma 006280.KS | $1.12B | -10% | -3% | 4% | 4.6× | n/a |
| Hualan Biological Engineering 002007.SZ | $3.20B | -17% | -11% | 17% | 26.7× | 15.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GRF.MC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +12.4% | +1.7% | 4th highest of 21 |
| 6-month return | +18.7% | +2.7% | 7th highest of 21 |
| Distance from 52-week high | -2.7% | -12.9% | 4th highest of 21 |
| Revenue growth (TTM) | +1.0% | +13.9% | 3rd lowest of 21 |
| Operating margin | 16.4% | 13.8% | 10th highest of 21 |
| Forward P/E | 13.1× | 19.2× | 3rd cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | 7.1% | 8.8% | 7th least demanding of 15 |
| Growth delivered (Del g) | +7.1% | +9.7% | 3rd lowest of 15 |
| Hurdle (Req g minus delivered) | -0.0 pp | -4.5 pp | 7th most demanding of 15 |
| ROIC minus cost of capital | -2.8 pp | +3.1 pp | 4th lowest of 19 |
| EV / EBITDA | 10.6× | 23.1× | 3rd cheapest of 12 |
| Net debt / EBITDA | 5.2× | -0.3× | most indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Grifols GRF.MC | Spain | $7.48B | +19% | +1% | 16% | 13.1× | 7.1% | +7.1% |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.47B | +75% | +58% | 14% | 56.6× | 10.4% | +45.5% |
| Corcept Therapeutics CORT | United States | $7.42B | +15% | +30% | 12% | 15.3× | 23.9% | +16.6% |
| Shanghai Fosun Pharmaceutical (Group) 600196.SS | China | $7.57B | -14% | +8% | 6% | 14.8× | 2.9% | +6.6% |
| Amneal Pharmaceuticals AMRX | United States | $7.62B | +79% | +9% | 16% | 19.2× | 17.2% | +8.7% |
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 15.3× | -6.8% | +10.8% |
| Asymchem Laboratories (Tianjin) 002821.SZ | China | $7.27B | +20% | +18% | 17% | 37.4× | n/a | n/a |
| Cytokinetics CYTK | United States | $7.15B | -35% | +30% | -625% | n/a | n/a | n/a |
| ImmunityBio IBRX | United States | $7.13B | -17% | +121% | -150% | n/a | n/a | n/a |
| Alkermes Public ALKS | United States | $7.87B | +27% | +15% | 5% | n/a | 32.5% | +7.3% |
| Bachem BANB.SW | Switzerland | $7.06B | 0% | +5% | 19% | 32.4× | n/a | n/a |
| ALK-abello A/S ALK-B.CO | Denmark | $7.94B | -8% | +16% | 26% | 34.8× | 7.3% | +12.6% |
| Akeso 9926.HK | Hong Kong | $7.01B | -48% | +42% | -25% | n/a | n/a | n/a |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.98B | +10% | 0% | 17% | 33.1× | 27.3% | +9.4% |
| Shanghai Pharmaceuticals 601607.SS | China | $8.23B | 0% | +4% | 3% | 11.2× | -10.1% | +8.1% |
| Rhythm Pharmaceuticals RYTM | United States | $8.25B | +31% | +61% | -67% | n/a | n/a | n/a |
| Protagonist Therapeutics PTGX | United States | $8.30B | +26% | +164% | 59% | 1,532.5× | 17.5% | +10.0% |
| Huadong Medicine 000963.SZ | China | $6.69B | -18% | +2% | 9% | 12.5× | -3.9% | +5.3% |
| Alkem Laboratories ALKEM.NS | India | $6.69B | -5% | +13% | 17% | 27.3× | 25.0% | +10.7% |
| Kyowa Kirin 4151.T | Japan | $8.43B | +9% | +10% | 24% | 16.4× | -4.7% | +9.3% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% | +18.4% |